Answers are grounded in this paper and cite their sources.
Tuberculosis remains a major health burden around the world. With the emergence of multi-drug-resistant and extensively drug-resistant Mycobacterium tuberculosis, the need for alternative antimicrobial strategies has increased. Bacteriophages can specifically infect and lyse bacteria, thereby having the potential for the treatment of tuberculosis. Administration via pulmonary delivery may offer a means of concentrating viable bacteriophages at the infection site within the deep lung while reducing systemic exposure. This review examines the pathophysiological and intracellular barriers relevant to pulmonary TB and evaluates current strategies for aerosolized phage delivery, including nebulization, dry-powder formulations, and macrophage-targeted delivery systems. Preclinical studies demonstrate promising aerosol performance, intracellular delivery, and antimycobacterial activity, particularly through engineered dry powders and liposomal systems; however, direct clinical evidence in pulmonary TB remains limited. Major challenges include maintaining phage viability during aerosol generation and storage, penetrating granulomatous lesions, and delivering sufficient active phages to intracellular M. tuberculosis within alveolar macrophages. Future translation will depend on improving phage stability during aerosolization, achieving efficient alveolar and intracellular delivery, overcoming host and lesion barriers, and establishing standardized manufacturing, safety, and regulatory frameworks.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: